Pure Global AI
NCT06081920Recruiting

A Study of IBI363 in Subjects With Advanced Melanoma

A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma
Innovent Biologics (Suzhou) Co. Ltd.Phase 1/2ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Melanoma
Drug/Device/Intervention
IBI363
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Oct 19, 2023
End date
Jul 31, 2026
Enrollment
20 participants
Primary outcome

Phase Ⅰb: AE（Adverse event）,Phase Ⅰb: RP2D（Recommended phase 2 dose）,Phase Ⅱ：ORR（Objective response rate）

Summary

This is an open-label, multicenter Phase Ib/II study to evaluate the safety, tolerability,
 and efficacy of IBI363 in advanced melanoma patients

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06081920
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06081920 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Recruiting. The study focuses on Melanoma. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.